The Alternative TrkAIII Splice Variant Targets the Centrosome and Promotes Genetic Instability

The hypoxia-regulated alternative TrkAIII splice variant expressed by human neuroblastomas exhibits oncogenic potential, driven by in-frame exon 6 and 7 alternative splicing, leading to omission of the receptor extracellular immunoglobulin C₁ domain and several N-glycosylation sites. Here, we show that the TrkAIII oncogene promotes genetic instability by interacting with and exhibiting catalytic activity at the centrosome. This function depends upon intracellular TrkAIII accumulation and spontaneous interphase-restricted activation, in cytoplasmic tyrosine kinase (tk) domain orientation, predominantly within structures that closely associate with the fully assembled endoplasmic reticulum intermediate compartment and Golgi network. This facilitates TrkAIII tk-mediated binding of γ-tubulin, which is regulated by endogenous protein tyrosine phosphatases and geldanamycin-sensitive interaction with Hsp90, paving the way for TrkAIII recruitment to the centrosome. At the centrosome, TrkAIII differentially phosphorylates several centrosome-associated components, increases centrosome interaction with polo kinase 4, and decreases centrosome interaction with separase, the net results of which are centrosome amplification and increased genetic instability. The data characterize TrkAIII as a novel internal membrane-associated centrosome kinase, unveiling an important alternative mechanism to “classical” cell surface oncogenic receptor tk signaling through which stress-regulated alternative TrkAIII splicing influences the oncogenic process.Alternative splicing is fundamental for differential protein expression from the same gene and not only increases the proteomic complexity of higher organisms (29) but is also involved in cancer pathogenesis, activating several oncogenes and inactivating several oncosuppressors (17).The neurotrophin receptor tropomyosin-related kinase A (TrkA) is among the proto-oncogenes activated by alternative splicing, with a novel hypoxia-regulated oncogenic alternative TrkAIII splice variant recently identified in advanced-stage human neuroblastomas (NB) and primary glioblastomas (44, 45). In contrast to wild-type TrkAI/TrkAII, the expression of which is associated with better prognosis for NB, induces NB cell differentiation, exhibits a tumor suppressor function in NB models in vivo (9, 19, 22, 30, 44, 45), and may regulate both spontaneous and therapy-induced NB regression (30), TrkAIII is expressed by more-advanced-stage NB and exhibits oncogenic activity in NB models (44, 45). This has challenged the hypothesis of an exclusively tumor-suppressing function for TrkA in NB by providing a way through which tumor-suppressing signals from TrkA can be converted to oncogenic signals from TrkAIII during tumor progression.The oncogenic potential of TrkAIII, characterized by NIH 3T3 cell transforming and NB xenograft primary and metastatic tumor-promoting activity (44, 45), is driven by in-frame alternative splicing of exons 6 and 7. This results in the omission of the receptor extracellular immunoglobulin C₁ (Ig C₁) Ig-like domain and several N-glycosylation sites important in regulating TrkA cell surface expression and preventing ligand-independent activation (2, 44, 45, 48). As a consequence, and unlike TrkAI and TrkAII, TrkAIII is not expressed at the cell surface but accumulates in the intracellular membrane compartment, within which it exhibits spontaneous tyrosine kinase (tk) and phosphoinositol-3 kinase (PI3K) activity and induces chronic signaling through PI3K/Akt/NF-κB but not Ras/mitogen-activated protein kinase (MAPK), inducing a more stress-resistant, angiogenic, and tumorigenic NB cell phenotype (44, 45). This differs from ligand-activated cell surface TrkA, which signals transiently through Ras/MAPK in NB cells to induce differentiation and a less angiogenic and tumorigenic NB cell phenotype (9, 19, 22, 30, 44, 45). This difference in signaling provides a potential basis for the opposing tumor-suppressing and oncogenic effects of alternative TrkA splice variants, which may not only depend upon the dislocation of TrkAIII from cell surface caveolae, which are the sites of TrkAI expression and Ras/MAPK signal initiation (45, 48), but also TrkAIII-associated PI3K activity below the Ras/MAPK activation threshold and/or TrkAIII-associated PI3K antagonism of Raf/MEK/extracellular signal-regulated kinase signaling (44). Signal transduction from intracellular TrkAIII bears close resemblance to the transient signaling through PI3K/Akt/NF-κB but not Ras/MAPK induced by A2a adenosine receptor/c-Src-mediated transactivation of immature TrkAI within the Golgi network (GN) (37), suggesting that the intracellular localization of TrkAIII is a critical determinant of both differential signaling and oncogenic potential.Intracellular nonnuclear membranes are separated into the endoplasmic reticulum (ER), ER-GN intermediate compartment (ERGIC), GN, and transport vesicles, which assemble around, integrate, and interact with the centrosome (38). The centrosome, comprised of two centrioles embedded within a pericentriolar matrix of over 100 proteins, including γ-tubulin, acts as the major microtubule-organizing center and orchestrates the assembly, organization, and integration of the ER, ERGIC, GN, and associated vesicles (38). The centrosome also maintains genomic integrity by duplicating once per cell cycle S phase, ensuring bipolar mitotic spindle formation, accurate chromosome segregation, and the inheritance of a single centrosome by each daughter cell (23).Centrosome duplication is tightly regulated by protein kinases Aurora-A and -B, polo kinases 1 and 4 (Plk-1 and Plk-4), Cdk2, PI3K, Zyg-1, Syk, Nek2, regulators Pin-1 and separase, and related phosphatases (11, 12, 18, 31, 42, 47, 53). The deregulation of centrosome duplication leads to centrosome amplification and subsequently to aberrant mitotic spindle formation, which promotes aneuploidy and polyploidy. These manifestations of genetic instability represent hallmarks of malignancy and drive tumor progression by promoting a more malignant phenotype (11, 12, 26, 35, 49). Centrosome amplification and subsequent genetic instability are induced by kinases that target the centrosome, the loss of centrosome-associated kinase inhibitors, altered levels of centrosome-associated regulators, and oncosuppressor inactivation (6, 7, 11, 12, 35, 40, 42, 49, 53).The localization of TrkAIII to internal membranes, as a prerequisite for oncogenic activity (44, 45), makes identification of the membrane context within which TrkAIII exhibits activity and novel substrate interactions within this environment important in elucidating how TrkAIII exerts oncogenic potential. In the present study, we unveil a novel oncogenic mechanism for TrkAIII by demonstrating that TrkAIII activation within membranes that associate closely with the assembled ER/ERGIC/GN facilitates recruitment to the centrosome, results in centrosome amplification, and promotes genetic instability.